A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumors

Effect of BI 811283, a novel inhibitor of Aurora B kinase, on tumor senescence and apoptosis.

(2017) U. Gürtler et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy

(2015) G. Borthakur et al.   HAEMATOLOGICA

A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy

(2015) G. Borthakur et al.   HAEMATOLOGICA

Aurora Kinase Inhibitors: Current Status and Outlook

(2015) Vassilios Bavetsias et al.   Frontiers in Oncology

Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: a multi-tumour, multi-institutional phase II study

(2014) P. Schoffski et al.   ANNALS OF ONCOLOGY

A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors

(2014) Christian Dittrich et al.   INVESTIGATIONAL NEW DRUGS

Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia

(2013) Hagop M. Kantarjian et al.   CANCER

Phase I Study Assessing the Safety and Tolerability of Barasertib (AZD1152) With Low-Dose Cytosine Arabinoside in Elderly Patients With AML

(2013) Hagop M. Kantarjian et al.   Clinical Lymphoma Myeloma & Leukemia

Aurora at the pole and equator: overlapping functions of Aurora kinases in the mitotic spindle

(2013) H. Hochegger et al.   Open Biology

Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure

(2012) Hielke J. Meulenbeld et al.   BJU INTERNATIONAL

Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors

(2012) A. Cervantes et al.   CLINICAL CANCER RESEARCH

Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations

(2012) E. C. Dees et al.   CLINICAL CANCER RESEARCH

Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma

(2012) Ursula A. Matulonis et al.   GYNECOLOGIC ONCOLOGY

Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors

(2012) Gary K. Schwartz et al.   INVESTIGATIONAL NEW DRUGS

Aurora kinase inhibitors: Progress towards the clinic

(2012) Madhu Kollareddy et al.   INVESTIGATIONAL NEW DRUGS

Mitosis-targeted anti-cancer therapies: where they stand

(2012) K-S Chan et al.   Cell Death & Disease

Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia

(2011) B. Lowenberg et al.   BLOOD

Abstract 1080: Molecular and cellular pharmacology of BI 811283, a potent inhibitor of Aurora B kinase

(2011) Ulrike Tontsch-Grunt et al.   CANCER RESEARCH

Abstract 1082: BI 811283, a potent inhibitor of the mitotic kinase Aurora B, shows dose- and schedule-dependent efficacy in human cancer xenograft models

(2011) Ulrich Gürtler et al.   CANCER RESEARCH

Feedback Control in Sensing Chromosome Biorientation by the Aurora B Kinase

(2011) Kevan J. Salimian et al.   CURRENT BIOLOGY

Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours

(2011) Patrick Schöffski et al.   EUROPEAN JOURNAL OF CANCER

A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia

(2011) Kosuke Tsuboi et al.   LEUKEMIA RESEARCH

Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors

(2010) D. S. Boss et al.   ANNALS OF ONCOLOGY

Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors

(2010) Anne M. Traynor et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I Study of the Selective Aurora A Kinase Inhibitor MLN8054 in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Pharmacodynamics

(2010) T. Macarulla et al.   MOLECULAR CANCER THERAPEUTICS

Sensing centromere tension: Aurora B and the regulation of kinetochore function

(2010) Michael A. Lampson et al.   TRENDS IN CELL BIOLOGY

Microtubule Active Agents: Beyond the Taxane Frontier

(2008) P. G. Morris et al.   CLINICAL CANCER RESEARCH

Aurora Kinases as Anticancer Drug Targets

(2008) O. Gautschi et al.   CLINICAL CANCER RESEARCH